Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 68   

Articles published

PFE 34.28
price chart
Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced an agreement with Pfizer for ...
Verastem Inks Separate Deals for Wnt and FAK Inhibitors  Genetic Engineering News
Pfizer May Sink On New Drug Woes
Pfizer (PFE) has recently been struggling to get an edge in the pharmaceutical industry. Not only is it struggling to get a major drug approved, but it also is on the defensive in several ways.
Is Pfizer A Good Buy?
Pfizer has been involved in a series of acquisitions and sell offs, some cheered and some criticized by investors. They recently sold off their nutrition business to Nestle for $11.9 billion.
Pfizer Needs Big Earnings Beat  TheStreet.com
Pfizer Defends $25 Fair Value With Lyrica Patent Lawsuit Win  Trefis
For Pfizer, Boston's medical labs a lure
Pfizer Inc., the world's largest pharmaceutical company, has a storied history of hunting for blockbuster drugs in its own labs.
Why We Think Pfizer Remains Significantly Undervalued
If a company is undervalued both on a DCF and on a relative valuation basis and is showing improvement in technical and momentum indicators, it scores high on our scale.
Pfizer Announces Topline Results Of First Of Four Studies In Bapineuzumab ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC ...
Hopes dim for Alzheimer's trials after Pfizer failure  Reuters
Pfizer-J&J Alzheimer's Drug Fails to Aid Cognition  Bloomberg
Pharmacies Sue Pfizer Over Lipitor
Five retailers joined a legal battle against Pfizer Inc., accusing the drug maker of using anticompetitive tactics to delay the introduction of competing generic copies of Pfizer's blockbuster cholesterol-lowering pill Lipitor.
Pfizer sued by retailers for generic Lipitor delay  Fox News
Parsing Talk Surrounding Pfizer's Mystery Drug At Antares  Seeking Alpha
Pfizer yanks breast, colon claims for Centrum vitamins
"The company disagrees with CSPI's concerns, but has agreed to make these changes in order to fully resolve the issues raised by the organization," Pfizer said in a statement provided on Thursday. A company spokesman declined to elaborate when asked ...
Pfizer to remove "breast health" and "colon health" ...  CBS News
Centrum Drops Breast And Colon Health Claims Amid Deceptive Advertising ...  Huffington Post
PFIZER INC. : Summary Notice Of Pendency Of Class Action
If you have not yet received the full printed Notice, you may obtain copies of this document by contacting the Notice Administrator at: Pfizer Securities Litigation, Notice Administrator, P.O. Box 3410, Portland, OR 97208-3410, (888) 236-0464, www.
Pfizer to return rights to three Acura products
Pfizer Inc will return three products it was developing using Acura Pharmaceuticals Inc's abuse-resistant technology, Acura said on Friday.
Pfizer Terminates License Agreement With Acura For 3 Development Stage ...  RTT News